About Huminsulin range Type 1 and type 2 diabetes mellitus are treated with the Huminsulin product line, which also helps adults and kids better control their blood sugar levels.

These generic granules are equivalent to Vertex Pharmaceuticals' 'Kalydeco' oral granules in the same strengths.

Global pharma major Lupin Limited on Monday announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. According to the company ...

The Huminsulin range is indicated for type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children. | Photo Credit: vitapix Drugmaker Lupin Ltd has acquired ...

This comes after the company on Monday announced the acquisition of Huminsulin from Lilly to enhance its diabetes portfolio. Lupin has been marketing the Huminsulin range of products comprising of ...

Lupin Ltd., a global pharmaceutical company, announced on December 30, the acquisition of the Huminsulin range of products in India from Eli Lilly and Company. The financial terms of the deal were ...

Lupin's Pithampur manufacturing unit produces both APIs (Active Pharmaceutical Ingredients) and finished products ...

Even as the global diabetes war continues to rage, Indian pharmaceutical companies are emerging from the shadows, armed with ...

Stocks like Rail Vikas Nigam, CESC, Dhanlaxmi Bank, Jubilant Ingrevia, Adani Green Energy, Archean Chemical Industries, Century Enka, Bank of India, Prataap Snacks, Power Grid Corporation of India, ...

Global pharma major Lupin Limited announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin ...

Lupin Ltd has announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio for an unspecified amount. Lupin has been marketing the ...

Pharma major Lupin has acquired Huminsulin brand in India from Eli Lilly, in an effort to enhance its diabetes portfolio, the company said in an exchange filing on December 30. Lupin had been ...